In the last trading session, 1.67 million shares of the Taysha Gene Therapies Inc (NASDAQ:TSHA) were traded, and its beta was 0.87. Most recently the company’s share price was $1.77, and it changed around $0.11 or 6.63% from the last close, which brings the market valuation of the company to $362.85M. TSHA currently trades at a discount to its 52-week high of $4.32, offering almost -144.07% off that amount. The share price’s 52-week low was $1.19, which indicates that the current value has risen by an impressive 32.77% since then. We note from Taysha Gene Therapies Inc’s average daily trading volume that its 10-day average is 1.79 million shares, with the 3-month average coming to 1.96 million.
Taysha Gene Therapies Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.10. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended TSHA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA has showed a green trend with a performance of 6.63% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8700 on recent trading dayincreased the stock’s daily price by 5.35%. The company’s shares are currently up 2.31% year-to-date, but still up 1.72% over the last five days. On the other hand, Taysha Gene Therapies Inc (NASDAQ:TSHA) is 7.27% up in the 30-day period. We can see from the shorts that 25.53 million shares have been sold at a short interest cover period of 12.8 day(s).
The consensus price target as assigned by Wall Street analysts is $8.5, which translates to bulls needing to increase their stock price by 79.18% from its current value. Analyst projections state that TSHA is forecast to be at a low of $5 and a high of $44.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -63.99%. Taysha Gene Therapies Inc earnings are expected to increase by -1.44% in 2025, but the outlook is negative -2.46% per year for the next five years.
TSHA Dividends
Taysha Gene Therapies Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 18.34% of Taysha Gene Therapies Inc shares, and 82.14% of them are in the hands of institutional investors. The stock currently has a share float of 100.59%. Taysha Gene Therapies Inc stock is held by 166.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 9.1103% of the shares, which is about 21.21 million shares worth $47.51 million.
RTW INVESTMENTS, LP, with 8.075% or 18.8 million shares worth $42.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.85 shares worth $8.58 million, making up 2.36% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 4.72 shares worth around $8.35 million, which represents about 2.30% of the total shares outstanding.
